Rebecsinib
{{Short description|Chemical compound}}
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{infobox drug
| drug_name = Rebecsinib
| image = Rebecsinib_structure.png
| legal_UK =
| legal_DE =
| C = 31 | H = 50 | O = 9
| IUPAC_name = (2S,3S,6S,7R,10S,E)-7,10-dihydroxy-2-((2E,4E,6R,7S)-7-hydroxy-7-((2R,3R)-3-((2R,3S)-3-methoxypentan-2-yl)oxiran-2-yl)-6-methylhepta-2,4-dien-2-yl)-3,7-dimethyl-12-oxooxacyclododec-4-en-6-yl acetate
| CAS_number = 2598242-04-5
| ChEBI = 226528
| ChemSpiderID = 8091622
| PubChem = 9915974
| UNII =
| ChEMBL =
| StdInChI= 1S/C31H50O9/c1-9-24(37-8)21(5)29-30(40-29)27(35)18(2)11-10-12-19(3)28-20(4)13-14-25(38-22(6)32)31(7,36)16-15-23(33)17-26(34)39-28/h10-14,18,20-21,23-25,27-30,33,35-36H,9,15-17H2,1-8H3/b11-10+,14-13+,19-12+
| StdInChIKey = LDCZLUDGHYDTHV-FPZDJJGISA-N
| SMILES = CO[C@@H](CC)[C@@H](C)[C@H]1O[C@@H]1[C@@H](O)[C@H](C)\C=C\C=C(/C)[C@@H]1OC(=O)C[C@H](O)CC[C@@](C)(O)[C@@H](OC(C)=O)\C=C\[C@@H]1C
}}
Rebecsinib (17S-FD-895) is an experimental anticancer medication derived by modification of the natural product Pladienolide B, which acts as an inhibitor of splicing-mediated activation of the enzyme ADAR1, and is in development as a potential treatment for leukemia.{{cite journal | vauthors = Butler MS | title = Remediating cancer via splicing modulation | journal = Journal of Medicinal Chemistry | volume = 56 | issue = 17 | pages = 6573–6575 | date = September 2013 | doi = 10.1021/jm401289z | pmid = 23981063 }}{{cite journal | vauthors = León B, Kashyap MK, Chan WC, Krug KA, Castro JE, La Clair JJ, Burkart MD | title = A Challenging Pie to Splice: Drugging the Spliceosome | journal = Angewandte Chemie | volume = 56 | issue = 40 | pages = 12052–12063 | date = September 2017 | doi = 10.1002/anie.201701065 | pmid = 28371109 | pmc = 6311392 }}{{cite journal | vauthors = van der Werf I, Mondala PK, Steel SK, Balaian L, Ladel L, Mason CN, Diep RH, Pham J, Cloos J, Kaspers GJ, Chan WC, Mark A, La Clair JJ, Wentworth P, Fisch KM, Crews LA, Whisenant TC, Burkart MD, Donohoe ME, Jamieson CH | title = Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells | journal = Cell Reports. Medicine | volume = 4 | issue = 3 | pages = 100962 | date = March 2023 | doi = 10.1016/j.xcrm.2023.100962 | pmid = 36889320 | pmc = 10040387 }}{{cite journal | vauthors = Crews LA, Ma W, Ladel L, Pham J, Balaian L, Steel SK, Mondala PK, Diep RH, Wu CN, Mason CN, van der Werf I, Oliver I, Reynoso E, Pineda G, Whisenant TC, Wentworth P, La Clair JJ, Jiang Q, Burkart MD, Jamieson CH | title = Reversal of malignant ADAR1 splice isoform switching with Rebecsinib | journal = Cell Stem Cell | volume = 30 | issue = 3 | pages = 250–263.e6 | date = March 2023 | doi = 10.1016/j.stem.2023.01.008 | pmid = 36803553 | pmc = 10134781 }}{{cite journal | vauthors = Murphy LA, Winters AC | title = Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells | journal = Biomedicines | volume = 11 | issue = 12 | date = December 2023 | page = 3248 | doi = 10.3390/biomedicines11123248 | doi-access = free | pmid = 38137469 | pmc = 10741170 }}